EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer.
about
Genetic and epigenetic markers in colorectal cancer screening: recent advances.Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.Kinases and cancerEGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma.Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with 64Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts.
P2860
EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
EGFR Gene Amplification and KR ...... Metastatic Colorectal Cancer.
@en
EGFR Gene Amplification and KR ...... Metastatic Colorectal Cancer.
@nl
type
label
EGFR Gene Amplification and KR ...... Metastatic Colorectal Cancer.
@en
EGFR Gene Amplification and KR ...... Metastatic Colorectal Cancer.
@nl
prefLabel
EGFR Gene Amplification and KR ...... Metastatic Colorectal Cancer.
@en
EGFR Gene Amplification and KR ...... Metastatic Colorectal Cancer.
@nl
P2093
P2860
P1476
EGFR Gene Amplification and KR ...... Metastatic Colorectal Cancer.
@en
P2093
Jinru Shia
Philip B Paty
Sajid A Khan
Zhaoshi Zeng
P2860
P2888
P304
P356
10.1007/S12253-016-0166-2
P577
2016-12-26T00:00:00Z